Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

For its “Allegra Airways” campaign, the allergy medication brand used real-time pollen and air pollution data to find pockets ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

To combat this, allergy medication Allegra created Allegra Airways, a website designed to help find and map real-time routes ...

Global pharmaceutical company Sanofi is partnering with Healx, a U.K.-based clinical-stage biotech specializing in rare diseases, to use its artificial intelligence to identify novel rare disease ...

However, on October 17, J.P. Morgan maintained a Hold rating on Sanofi (Other OTC: SNYNF ... production and distribution of pharmaceutical products. It operates through the following business ...

With its decision, Sanofi joined peers Johnson & Johnson, Pfizer and GSK in hiving off businesses that sell over-the-counter medicines ... sell different types of products and services to both ...

which is the third-largest business in the world in the over-the-counter and vitamins, minerals & supplements market, according to Sanofi. The French pharma company said the deal, which saw CD&R ...

including details by product and quarter, are expected to be provided in the coming weeks. After the closing of the transaction, the share of results from the retained minority interest in Opella will ...